Home/Filings/4/0001209191-21-013821
4//SEC Filing

Wiley Matthew T. 4

Accession 0001209191-21-013821

CIK 0001566044other

Filed

Feb 23, 7:00 PM ET

Accepted

Feb 24, 4:40 PM ET

Size

7.5 KB

Accession

0001209191-21-013821

Insider Transaction Report

Form 4
Period: 2021-02-22
Wiley Matthew T.
Chief Commercial Officer
Transactions
  • Award

    Stock Options

    2021-02-22+64,57564,575 total
    Exercise: $8.33Exp: 2031-02-22Common Stock (64,575 underlying)
  • Award

    Common Stock

    2021-02-22+27,675116,970 total
Footnotes (2)
  • [F1]Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.
  • [F2]The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

Issuer

VYNE Therapeutics Inc.

CIK 0001566044

Entity typeother

Related Parties

1
  • filerCIK 0001759703

Filing Metadata

Form type
4
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 4:40 PM ET
Size
7.5 KB